{"id":177750,"date":"2026-01-26T22:39:02","date_gmt":"2026-01-27T03:39:02","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=177750"},"modified":"2026-01-26T22:39:02","modified_gmt":"2026-01-27T03:39:02","slug":"innova-captab-limited-accelerating-strategic-growth-with-strong-q3-and-9-month-fy26-performance","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/innova-captab-limited-accelerating-strategic-growth-with-strong-q3-and-9-month-fy26-performance\/","title":{"rendered":"Innova Captab Limited Accelerating Strategic Growth with Strong Q3 and 9-Month FY26 Performance"},"content":{"rendered":"\n<p>Innova Captab Limited (NSE: INNOVACAP\/BSE: 544067), is a leading integrated pharmaceutical company with a comprehensive business model spanning the entire value chain, including research and development, manufacturing, and marketing. The company serves as a preferred CDMO partner for prominent global pharmaceutical companies while maintaining a robust branded generics business in over 60 countries.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Q3 &amp; 9M FY26 Earnings Highlights<\/strong><\/h2>\n\n\n\n<p>The company delivered a stellar financial performance for the period.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Revenue from Operations: Surged by 42% YoY in Q3 FY26 to \u20b9450.3 crore and 27% YoY for 9M FY26 to \u20b91,182.2 crore.<\/li>\n\n\n\n<li>EBITDA: Grew by 40% YoY to \u20b971.1 crore in Q3 FY26, with margins at 15.8%.<\/li>\n\n\n\n<li>Profit After Tax (PAT): Increased by 23% YoY to \u20b942.1 crore for the quarter.<\/li>\n<\/ul>\n\n\n\n<p>Profitability metrics remained healthy despite expansion costs. EBITDA for Q3 FY26 rose 39.6% YoY to \u20b971.1 crore (15.8% margin), while 9M FY26 EBITDA reached \u20b9183.7 crore, growing 24.8%. Profit After Tax (PAT) for the quarter stood at \u20b942.1 crore (+23.2% YoY), bringing the 9M FY26 PAT to \u20b9102.8 crore, a 4.2% increase from the prior year.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"535\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2-1024x535.png\" alt=\"\" class=\"wp-image-177752\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2-1024x535.png 1024w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2-300x157.png 300w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2-768x401.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Innova-2.png 1180w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Segment Performance Update<\/strong><\/h2>\n\n\n\n<p>The company&#8217;s growth was driven by diversified performance across its core segments.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>CDMO Services: Revenue for this segment grew 29% YoY in Q3 FY26 to \u20b9298.7 crore and 18% in 9M FY26 to \u20b9813.9 crore. This was fueled by deeper engagement with its base of 300+ global customers.<\/li>\n\n\n\n<li>Branded Generics: This vertical saw sharp growth of 79% in Q3 FY26 (\u20b9151.6 crore) and 56% in 9M FY26 (\u20b9368.4 crore), driven by expanded footprints in India and international markets.<\/li>\n\n\n\n<li>Export Mix: International contributions accounted for 35% of total revenue in Q3 FY26 and 32% across the 9M FY26 period.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Management Commentary<\/strong><\/h2>\n\n\n\n<p>Managing Director, Vinay Lohariwala attributed the results to &#8220;disciplined execution&#8221; and robust output across all manufacturing facilities. A major highlight was the receipt of GMP Compliance certifications from UK-MHRA for the Baddi facility and PIC\/s (SMDC, Ukraine) for the Jammu facility, which management views as a testament to their adherence to global quality standards.<\/p>\n\n\n\n<p>Management provided clear guidance for its Jammu Plant, which was commercialized in January 2025. ICL expects to ramp up capacity utilization at this state-of-the-art facility to optimum levels over the next 5-6 years. Furthermore, the company aims to unlock long-term synergies through the integration of Sharon Bio Medicine Ltd, particularly in Formulation and API offerings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Broader Industry Trends<\/strong><\/h2>\n\n\n\n<p>The pharmaceutical industry is seeing a shift toward integrated players who can offer high-quality, affordable solutions at scale. Innova Captab is positioning itself to benefit from this by expanding its R&amp;D capabilities and leveraging the &#8220;New Central Sector Scheme&#8221; for industrial development in Jammu &amp; Kashmir, which provides GST-linked incentives and capital interest subventions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Takeaway<\/strong> <\/h2>\n\n\n\n<p>Innova Captab&#8217;s Q3 and 9M FY26 performance reflects a successful transition into a high-growth phase. With the commercialization of the Jammu facility and a growing global footprint, the company is well-positioned to maintain consistent, high-quality growth while creating significant long-term stakeholder value.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innova Captab Limited (NSE: INNOVACAP\/BSE: 544067), is a leading integrated pharmaceutical company with a comprehensive business model spanning the entire value chain, including research and development, manufacturing, and marketing. The company serves as a preferred CDMO partner for prominent global pharmaceutical companies while maintaining a robust branded generics business in over 60 countries. Q3 &amp; [&hellip;]<\/p>\n","protected":false},"author":2378,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,5747],"tags":[13743,1115,14609],"class_list":["post-177750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-healthcare-stocks","tag-health-care","tag-pharmaceuticals","tag-results"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":178128,"url":"https:\/\/alphastreet.com\/india\/innova-captab-q3-fy26-earnings-results\/","url_meta":{"origin":177750,"position":0},"title":"Innova Captab Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 28, 2026","format":false,"excerpt":"Executive Summary Innova Captab Ltd reported Q3FY26 revenues of \u20b9450 crore, up 42.41% YoY, with consolidated net profit rising 23.53% to \u20b942 crore. Total expenses increased 44.0% YoY to \u20b9396 crore, reflecting strong revenue momentum despite cost pressures. Revenue & Growth Revenues jumped to \u20b9450.00 crore in Q3FY26 from \u20b9316.00\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/INNO.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177745,"url":"https:\/\/alphastreet.com\/india\/innova-captab-limited-reports-robust-q3-fy26-results-revenue-surges-42-amid-global-expansion\/","url_meta":{"origin":177750,"position":1},"title":"Innova Captab Limited Reports Robust Q3 FY26 Results. Revenue Surges 42% Amid Global Expansion","author":"Staff Correspondent","date":"January 26, 2026","format":false,"excerpt":"Innova Captab Limited (NSE: INNOVACAP | BSE: 544067) announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, on January 23, 2026. The company, a leading integrated pharmaceutical player, demonstrated a significant acceleration in revenue growth driven by its dual focus on Contract Development\u2026","rel":"","context":"In &quot;LATEST&quot;","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177762,"url":"https:\/\/alphastreet.com\/india\/innova-captab-limited-performance-market-environment-and-competitive-position\/","url_meta":{"origin":177750,"position":2},"title":"Innova Captab Limited Performance, Market Environment, and Competitive Position","author":"Staff Correspondent","date":"January 26, 2026","format":false,"excerpt":"Innova Captab Limited (NSE: INNOVACAP) has emerged as a noteworthy player in India's pharmaceutical landscape, combining contract development and manufacturing (CDMO) services with a branded generics business. In recent quarters, the company has delivered strong top-line growth coupled with improving profitability, reflecting both operational execution and expanding market reach. In\u2026","rel":"","context":"In &quot;LATEST&quot;","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":179824,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-reports-q3fy26-with-revenue-growth-and-ebitda-margin-expansion\/","url_meta":{"origin":177750,"position":3},"title":"Marksans Pharma Reports Q3FY26 with Revenue Growth and EBITDA Margin Expansion","author":"Staff Correspondent","date":"February 6, 2026","format":false,"excerpt":"About Marksans Pharma Limited Marksans Pharma Limited (NSE: MARKSANS) is an Indian pharmaceutical company headquartered in Mumbai, India, founded in 1992. It specializes in the research, development, manufacturing and marketing of pharmaceutical formulations, offering both over-the-counter (OTC) and prescription medicines across various therapeutic areas such as pain management, cardiovascular health,\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173228,"url":"https:\/\/alphastreet.com\/india\/srf-q3-fy26-earnings-results\/","url_meta":{"origin":177750,"position":4},"title":"SRF Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 21, 2026","format":false,"excerpt":"Incorporated in 1970, SRF Ltd manufactures and sells technical textiles, chemicals, packaging films, aluminum foils, and other polymers. Q3 FY26 Earnings Results Gross Operating Revenue: \u20b93,712.5 crore, up 6.3% YoY from \u20b93,491.3 crore in Q3 FY25; up 1.99% QoQ from ~\u20b93,640 crore in Q2 FY26. Revenue from Operations: \u20b93,712.53 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"SRF Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/SRF-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":181128,"url":"https:\/\/alphastreet.com\/india\/marathon-nextgen-realty-posts-%e2%82%b9161-crore-9m-fy26-pat-up-18-yoy-q3-revenue-at-%e2%82%b9141-crore\/","url_meta":{"origin":177750,"position":5},"title":"Marathon Nextgen Realty Posts \u20b9161 Crore 9M FY26 PAT, Up 18% YoY; Q3 Revenue at \u20b9141 Crore","author":"Staff Correspondent","date":"February 17, 2026","format":false,"excerpt":"Financial Performance Marathon Nextgen Realty reported consolidated revenue of \u20b9141 crore for Q3 FY26 and \u20b9487 crore for the first nine months of the fiscal. EBITDA stood at \u20b939 crore in Q3 and \u20b9200 crore for 9M FY26, while profit after tax (PAT) came in at \u20b933 crore and \u20b9161\u2026","rel":"","context":"In &quot;Finance&quot;","block_context":{"text":"Finance","link":"https:\/\/alphastreet.com\/india\/category\/finance-stocks\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2378"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177750"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177750\/revisions"}],"predecessor-version":[{"id":177753,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177750\/revisions\/177753"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}